Gene therapy joins forces with chemo and immunotherapy to fight bladder cancer
NCT ID NCT07332351
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a gene therapy called nadofaragene firadenovec to standard chemotherapy and immunotherapy can improve outcomes for people with muscle invasive bladder cancer before they have their bladder removed. The gene therapy is placed directly into the bladder and helps it produce a natural protein that fights cancer. About 33 participants will receive the combination, and researchers will check if the cancer disappears completely after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nadofaragene firadenovec (gene therapy), durvalumab (immunotherapy), gemcitabine and cisplatin (chemotherapy)
- What this could lead to
- If successful, this combination could improve the chance of eliminating all cancer before bladder removal surgery, potentially reducing recurrence and improving survival.
- What could go wrong
- This is an early phase 2 trial with only 33 participants, so results may not apply broadly. Adding gene therapy to standard treatment could increase side effects, and the study is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could detect bladder Cancer's return — a trial puts it to the test
- New combination aims to save bladders in Muscle-Invasive cancer
- Needle-Sized device could reveal which bladder cancer drug works best
- Bladder cancer radiation trial halted early – only 2 patients enrolled
- Experimental triple therapy for advanced cancers shows early promise but trial halted
- Bladder cancer drug trial halted early after enrolling just 4 patients